NCT07759323Not yet recruiting
Polygonatum Sibiricum Reduces Visceral Fat in Obese Adults
Polygonatum Sibiricum for Visceral Obesity and Related Metabolic Abnormalities: A Randomized Controlled Trial and Mechanistic Exploration
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Brief summary (registry, in English)
This study is being done to find out if a traditional Chinese herb called Polygonatum sibiricum (Huangjing) can help reduce belly fat and improve metabolic health in adults with visceral obesity. Visceral obesity means having too much fat stored deep inside the belly, around the organs. This type of fat is linked to a higher risk of diabetes, fatty liver, and heart disease. The study will include 66 adults with visceral obesity. Participants will be randomly assigned to one of two groups: One group will receive a Polygonatum sibiricum decoction (15 grams daily) plus standard lifestyle advice on diet and exercise. The other group will receive the same lifestyle advice only. The study will last for 12 weeks. Researchers will measure changes in visceral fat area, body weight, waist size, blood sugar, blood lipids, and liver fat. They will also look at gut bacteria and related markers to better understand how Polygonatum sibiricum might work. Participation involves 4 visits to the study site over the 12-week period. All participants will receive free health assessments and dietitian guidance. The study is not a treatment but a research study to test whether this herb has potential benefits for visceral obesity.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- First submitted
- 6 Aug 2026
- Start date
- 15 Aug 2026
- Primary completion date
- 30 Jul 2027
- Lead sponsor
- Zhejiang Provincial Tongde Hospital
- Diseases
- Obesity
- NCT number
- NCT07759323
What you commit to
- Study type: Interventional
- Planned participants: 66
- From 15 Aug 2026 to the primary completion date, 30 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous metabolic surgery or current use of weight-loss medications;
- Concomitant severe hyperglycemia or lipid metabolism disorders requiring immediate intensive treatment;
- Concomitant severe cardiovascular or cerebrovascular disease, or unstable medical condition;
- Allergy to or intolerance of any component of the investigational product;
Other illness
- Secondary obesity (e.g., caused by endocrine disorders such as hypothyroidism, Cushing's syndrome, or polycystic ovary syndrome);
- Malignant tumors, active infections, or autoimmune diseases;
- Any other conditions deemed unsuitable for participation in this study by the investigator.
Lab values
- Significant hepatic or renal dysfunction (e.g., ALT or AST \> 2-3 times the upper limit of normal, or eGFR \< 60 ml/min/1.73 m²);
Other
- Use of antibiotics, probiotics, or other agents that may affect gut microbiota within the past month;
- Pregnancy, lactation, or plans for pregnancy;
Who the study is looking for
- Age 18 to 65 years, male or female;
- Body mass index (BMI) ≥ 24 kg/m², or body fat percentage ≥ 25% for males or ≥ 30% for females, and visceral fat area ≥ 100 cm²;
- Body weight stable within the past 3 months, with fluctuation not exceeding 5%;
- Able to understand the study content, voluntarily sign the informed consent form, and willing to complete follow-up visits and required examinations as scheduled.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang Provincial Tongde Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.